Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

hu14.18-interleukin-2 fusion protein

(… in-ter-LOO-kin-2 FYOO-zhun PROH-teen)

An anticancer drug in which hu14.18, a monoclonal antibody, is combined with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers IL-2, which stimulates the immune system to destroy the cancer cells.

hu14.18-interleukin-2 fusion protein

Search NCI's Dictionary of Cancer Terms